What is Shingrix?
Shingrix is a vaccine used to prevent shingles, a painful rash caused by the herpes zoster virus. It is approved by the U.S. Food and Drug Administration (FDA) for use in adults aged 50 years and older. Shingrix is a brand-name, non-live, recombinant vaccine that contains no live virus. It is administered through intramuscular injection and requires two doses, with the second dose given 2-6 months after the first one.
Studies have shown that Shingrix is highly effective in preventing shingles, with over 90% efficacy in clinical trials. It contains a strong adjuvant, which is a substance that enhances the immune response, allowing it to offer longer-lasting protection than previous shingles vaccines. Shingrix is also approved by the World Health Organization (WHO) for its quality, safety, and efficacy standards.
Shingrix has some side effects that may occur after vaccination, such as pain and swelling at the injection site, as well as fever, headache, and fatigue. Most of these side effects are mild to moderate and go away after a few days. In rare cases, some people may experience more serious side effects, such as allergic reactions.
Shingrix is available in the United States and is covered by most insurance plans. The cost of the vaccine may vary depending on the provider and the location. Patients should talk to their healthcare provider if they have any questions or concerns about getting the vaccine.
In conclusion, Shingrix is a highly effective and safe vaccine used to prevent shingles in adults aged 50 years and older. It requires two doses, with the second dose given 2-6 months after the first one. While it may cause some mild to moderate side effects, the benefits of the vaccine far outweigh the risks. Patients should talk to their healthcare provider about getting the vaccine if they are eligible.
Frequently Asked Questions about shingrix
Recombinant zoster vaccine (RZV, Shingrix), has been in use since 2017 and is recommended by ACIP as the preferred shingles vaccine.
About Shingrix
It combines an antigen, glycoprotein E, with an adjuvant system, AS01B, and may help overcome the natural age-related decline in responses to immunisation that contributes to the challenge of protecting adults aged 50 and over from shingles.
About 1 out of every 3 people in the United States will develop shingles in their lifetime. Shingrix provides strong protection against shingles and long-term pain from the disease. Two doses of Shingrix are more than 90% effective at preventing shingles. So it's very important that you get this vaccine.
The main immunological component of Shingrix vaccine is glycoprotein E (gE), a protein found on the surface of varicella zoster virus (VZV). Immune exposure to gE protein stimulates the development of anti-gE antibodies, and therefore adaptive immunity to VZV.
A: Yes, Shingrix is an inactive vaccine so you can administer it with other inactive or live vaccines. If you administer Shingrix and another vaccine to someone on the same day, give them at different anatomical sites (e.g., different arms).
Shingrix contains only a small part of the varicella zoster virus that causes shingles. Shingrix does not contain any live varicella zoster virus.
FDA required GlaxoSmithKline (GSK), the manufacturer of Shingrix, to revise the Prescribing Information to include the following language in the Warnings and Precautions section: In a postmarketing observational study, an increased risk of GBS was observed during the 42 days following vaccination with Shingrix.
Medicinal ingredients: 1 dose (0.5 mL) contains 50 micrograms of glycoprotein E (gE) powder mixed with AS01B adjuvant suspension. gE is a protein found in the Varicella Zoster Virus. This protein is not infectious.
Reconstituted Shingrix vaccine contains recombinant VZV glycoprotein E antigen, sucrose, polysorbate 80, sodium dihydrogen phosphate dehydrate, dipotassium phosphate, QS-21, MPL, liposomes (dioleoyl phosphatidylcholine [DOPC] and cholesterol), phosphate-buffered solution, disodium phosphate anhydrous, potassium ...
Shingrix contains only a small part of the varicella zoster virus that causes shingles. Shingrix does not contain any live varicella zoster virus.
Shingrix contains only a small part of the varicella zoster virus that causes shingles. Shingrix does not contain any live varicella zoster virus.
The shingles vaccine available in the U.S., Shingrix®, contains a single protein from the surface of herpes zoster virus as well as two adjuvants: QS21 and monophosphoryl lipid A.
Official answer. The main difference is that Shingrix is more effective at preventing shingles (herpes zoster virus) than Zostavax (overall: 97.2% vs. 51%, respectively). Shingrix is an FDA-approved vaccine to help prevent the occurrence of herpes zoster (shingles).
SHINGRIX is given as a 2-dose series, with the second shot administered 2 to 6 months after the first shot. It's important to receive both shots of SHINGRIX. If you've already had your first dose, sign up for text, email, and voice reminders for your second dose.
SHINGRIX is owned by or licensed to the GSK group of companies.
FDA required GlaxoSmithKline (GSK), the manufacturer of Shingrix, to revise the Prescribing Information to include the following language in the Warnings and Precautions section: In a postmarketing observational study, an increased risk of GBS was observed during the 42 days following vaccination with Shingrix.
